Cover Story : Syneos Health

Syneos Health
Adding Value to Drug Discovery

Top 10 CRO Solution Providers 2020

CMIC Inc: Bioanalysis for non-clinical and clinical projects

CMIC’s skilled researchers provide deep expertise in small and large molecule bioanalysis, biomarker services and oligonucleotide bioanalysis expertise. Purpose built in 2010, CMIC Inc.’s contract bioanalytical and biomarker laboratory is located nearby Chicago O’Hare International Airport and is one of four global contract laboratories in the CMIC Holdings group.

Frontage Labs: Unlocking a New Era of Drug Discovery

Today, Frontage Labs stands as a value-added partner with a focus on solving customer’s the most significant and complex drug discovery and development challenges of its customers. In doing so, the company has enabled innovators, generic, and consumer health companies of all sizes to file IND, NDA, ANDA, BLA, and 505(b)(2) submissions in global markets, therebycontributing to theenabling successful development of important therapies and products for patients worldwide.

ICON: Delivering Flexible and Cost-Efficient CRO Services

The pharmaceutical industry is under muchtension in developing of drugs/devices todaydue to stricter regulations, changing technologies, and globalization, which stresses the current operational models and information infrastructure to the limits. Besides, the increasing pressure to constrain costs and expenditure while replenishing the dwindling development pipeline has remained unabated over the past few decades.

Namsa: Streamlining the Nitty-Grittiesof Medical Device Development

In today’s technology-drivenhealthcare sector, delivering a novel medical device to the market can be a tedious process, even when you’re familiar with the regulatory, reimbursement, and quality standards in the intended global markets. Besides, regulatory mandates and reimbursement systems are complex and vary widely across countries, making it critical for providers to understand potential barriers and the right means of reimbursing various devices. Consequently, many medical device manufacturersmay lack the properguidance and often find it hard toinitiate the best reimbursement strategies in their product development lifecycles.

Translate »